Sugi Predict

Sugi Predict / Compounds / SCHEMBL1823256

SCHEMBL1823256

SCHEMBL1823256

FC(F)(F)c1ccnc2[nH]ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCI P41743 4/20 0.53
▸ AXL P30530 1/20 0.53
▸ NUDT1 P36639 4/20 0.47
▸ AURKB Q96GD4 3/20 0.47
▸ JAK2 O60674 3/20 0.47
▸ JAK3 P52333 2/20 0.47
▸ IGF1R P08069 2/20 0.47
▸ DYRK1B Q9Y463 2/20 0.47
▸ IKBKB O14920 2/20 0.47
▸ CHUK O15111 2/20 0.47
▸ DAPK3 O43293 1/20 0.47
▸ PRKD3 O94806 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ PAK4 O96013 1/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ RET P07949 1/20 0.47
▸ FGFR1 P11362 1/20 0.47
▸ PRKACA P17612 1/20 0.47
▸ FLT1 P17948 1/20 0.47
▸ LTK P29376 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL179480 0.81 PRKCI (0.53) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL10124925 0.79 IGF1R (0.58) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL29938802 0.78 PRKCI (0.50) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL12915020 0.77 PRKCI (0.49) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL10298661 0.75 PRKCI (0.47) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL3719643 0.75 ALK (0.43) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL19286544 0.74 PRKCI (0.46) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL21062776 0.74 PRKCI (0.59) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL29605623 0.74 NUDT1 (0.61) PRKCIAXLNUDT1AURKBJAK2
SCHEMBL30788412 0.74 PRKCI (0.59) PRKCIAXLNUDT1AURKBJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066368-A1 DNA POLYMERASE THETA INHIBITOR AND USE THEREOF SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2025-02-27 — — US disclosed
WO-2024188246-A9 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海宇道生物技术有限公司 2024-12-05 — — WO disclosed
EP-4455129-A1 DNA POLYMERASE THETA INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2024-10-30 — — EP disclosed
WO-2024188246-A1 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海宇道生物技术有限公司 2024-09-19 — — WO disclosed
CN-118451067-A DNA polymerase theta inhibitor and application thereof 上海湃隆生物科技有限公司 2024-08-06 — — CN disclosed
WO-2023125918-A1 DNA POLYMERASE THETA INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2023-07-06 — — WO disclosed
EP-3268373-A1 TRICYCLIC DLK INHIBITORS AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2018-01-17 — — EP disclosed
US-9670201-B2 Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof PFIZER INC. (US) 2017-06-06 — — US disclosed
CN-106715416-A Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof 辉瑞大药厂 2017-05-24 — — CN disclosed
US-9617267-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-04-11 — — US disclosed
WO-2011063159-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-26 — — WO disclosed
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 — — US disclosed
CN-101778629-A Substituted pyrrolopyridine and pyrazolopyridine compounds useful as kinase modulators SGX PHARMACEUTICALS INC 2010-07-14 — — CN disclosed
EP-2056822-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX Pharmaceuticals, Inc. (US) 2009-05-13 — — EP disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 — — US disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 — — US disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 — — US disclosed
WO-2008150914-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-12-11 — — WO disclosed
WO-2008150914-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2008-12-11 — — WO disclosed
US-7227020-B2 Azaindoles AVENTIS PHARMA LIMITED (GB) 2007-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS PDXK, MAP3K4, PDPK1 PRKCI 674/4885AXL 599/4885NUDT1 2430/4885
US-20250066368-A1 DNA POLYMERASE THETA INHIBITOR AND USE THEREOF POLQ, POLB, POLM PRKCI 43/4885AXL 3606/4885NUDT1 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.